Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer

To evaluate the cardiac safety of anti-HER2-targeted therapy for early breast cancer; to investigate whether trastuzumab combined with pertuzumab increases cardiac toxicity compared with trastuzumab; to evaluate the predictive value of high-sensitivity Troponin (hs-TnI) and QTc for the cardiotoxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Li, Wang, Yan, Meng, Wenjing, Zhao, Weipeng, Tong, Zhongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395410/
https://www.ncbi.nlm.nih.gov/pubmed/35995984
http://dx.doi.org/10.1038/s41598-022-18342-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395410/
https://www.ncbi.nlm.nih.gov/pubmed/35995984
http://dx.doi.org/10.1038/s41598-022-18342-1

Ejemplares similares